Loading...
OTC Markets
Totals
Securities
12,222
Dollar Vol
$1.6B
Share Vol
1.5B
Trades
202,072

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

BVAXF
BioVaxys Technology Corp.

Ordinary Shares

0.016575

-0.00207

-11.13%

0.0161 / 0.019 (78195 x 420000)

Real-Time Best Bid & Ask: 01:03pm 07/22/2025
Delayed (15 Min) Trade Data: 12:01pm 07/22/2025
BioVaxys Technology Corp. Company Logo

146 Thirtieth Street

Suite 100

Etobicoke, ON M8W 3C4

Canada

Principal Executive Offices:

146 Thirtieth Street

Suite 100

Etobicoke, ONT M8W 3C4

Canada

Business Description
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© "neoantigen" tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological diseases. DPX™ is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical ...
More
Financial Reporting
Reporting Status
International Reporting: Canadian Securities Exchange
Audited Financials
Audited
Fiscal Year End
10/31
Company Officers & Contacts
James Passin
CEO

Mr. James Passin is a former hedge fund and private equity fund manager at FGS Advisors, LLC, an affiliate of New York-based Firebird Management LLC. He has 20 years of experience as a professional investor, a deep experience of financing and developing venture-stage companies, and directed and managed over $155 million of equity and debt investment into biotech companies including Avax Technologies, Inc., one of the world's first cellular immunotherapeutic vaccine companies. He is a director of several public companies, including TraceSafe Inc. (CSE: TSF) and BDSec JSC (MSE: BDS), is a Chartered Market Technician and member of the CMT Association.

Kenneth Kovan
COO, President

Mr. Kovan has over 30 years of experience in biopharmaceuticals commercial development. He recently served as Corporate Development Partner with Horizon Discovery plc in the United Kingdom, and is Managing Principal & Owner of Bingham Hill Ventures, a life sciences advisory practice he founded in 2012 that specializes in corporate development, technology licensing, and business planning. He is an experienced former biotech CEO and board member, and founder of biotechnology companies including the former Avax Technologies, Inc. Mr. Kovan's professional background includes several years in technology transfer with Thomas Jefferson University, Strategic Marketing with GlaxoSmithKline, and Global New Product Development with Wyeth-Ayerst Pharmaceuticals. His therapeutic experience includes infectious disease, antivirals, oncology, vaccines, cell/gene therapy, and gene editing. Mr. Kovan has a broad international business background, having launched pharma brands in Latin American and Asia/Pacific markets, and has worked in Europe for several years.

Christopher Padraig Cherry
CFO

Christopher Cherry has over 15 years of corporate accounting and audit experience, having been a Chartered Accountant (CA) since February 2009 and a Certified General Accountant (CGA) since 2004. Mr. Cherry has held a number of senior level positions, including as a Senior Accountant at KPMG and as an Auditor at Davidson and Co. LLP in Vancouver. Mr. Cherry has also served at the director and officer levels for a number of public mining companies. Mr. Cherry is the founder of Cherry Consulting, Ltd. Mr. Cherry earned a Bachelors of Technology in Accounting from the British Columbia Institute of Technology.

David Berd MD
Chief Med. Officer

Dr. David Berd is a medical oncologist with a lifelong record of clinical research in medical oncology and cancer immunotherapy. He cofounded cancer immunotherapy company AVAX Technologies and served as Chief Medical Officer 2005-2008. As National Director for Immunotherapy at Cancer Treatment Centers of America, Dr. Berd investigated the application of the AC vaccine to ovarian cancer. Previously, Dr. Berd was Professor of Medicine at Thomas Jefferson University, where for 20 years he conducted clinical research on melanoma immunotherapy. He also spent nine years as a research physician at Fox Chase Cancer Center. Over the course of his career, Dr. Berd has published more than 85 original papers in numerous medical journals alongside dozens of editorials, reviews and abstracts. He has ten issued patents dealing with cancer vaccines. Throughout his career, he has participated in national and international conferences on melanoma and cancer immunotherapy. Dr. Berd received his BS from Pennsylvania State University and his MD from Jefferson Medical College of Thomas Jefferson University.

Janet Elizabeth Francis
Other

Annika Tilley
Other

Franchesca Del-Barrio Alcanse
Other

Board of Directors
Anthony J Dutton

Anthony is a seasoned business executive and entrepreneur with a successful track record as an early stage investor and business founder. His areas of expertise are corporate finance, business development and strategic management. He is regularly engaged in developing strategic and financial plans for early stage and high growth companies. Anthony holds a BA in Economics from the University of British Columbia, a M.Arch from Dalhousie University and a MBA from the Cranfield School of Management in the United Kingdom. Anthony is a principal at Delu Corp., a strategic and financial advisory company and serves as a director of several Canadian public and private resource and energy focused companies.

Craig Loverock
Independent Director, Audit Committee Member, Compensation Committee Member

Craig Loverock, CPA, CA, is a Chartered Professional Accountant with over 25 years of experience in accounting and finance roles in Canada, the United States and England. Mr. Loverock has been the Chief Financial Officer and Corporate Secretary at Contagious Gaming Inc. since November 30, 2015, and currently serves as the Chief Financial Officer of Sproutly Canada, Inc. From October 2014 to May 2015, he served as the Chief Financial Officer of VoiceTrust Inc. From November 2012 to October 2014, he served as the Chief Financial Officer and Chief Compliance Officer of Quartz Capital Group Ltd. From January 2010 to November 2012, he provided Chief Financial Officer consulting services to a number of high-growth businesses. Mr. Loverock served as the Senior Financial Advisor to the Chairman at Magna International from August 2007 to January 2010. Mr. Loverock received his Chartered Accountant designation from the Institute of Chartered Accountants, Ontario in 1997.

James Passin
Audit Committee Member, Compensation Committee Member

Mr. James Passin is a former hedge fund and private equity fund manager at FGS Advisors, LLC, an affiliate of New York-based Firebird Management LLC. He has 20 years of experience as a professional investor, a deep experience of financing and developing venture-stage companies, and directed and managed over $155 million of equity and debt investment into biotech companies including Avax Technologies, Inc., one of the world's first cellular immunotherapeutic vaccine companies. He is a director of several public companies, including TraceSafe Inc. (CSE: TSF) and BDSec JSC (MSE: BDS), is a Chartered Market Technician and member of the CMT Association.

Other Company Insiders

None

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers
Accounting/Auditing Firm
Dale Matheson Carr-Hilton Labonte LLP

1140 West Pender Street

# 1500-1700

Vancouver, BC V6E EG1

Canada

Investment Bank
Enclave Capital LLC
Investment Bank
D12 Capital Markets Inc. and affiliate Foundation Markets Inc.

Canada

Securities Counsel
Barnet Goldberg Barrister & Solicitor

Canada

Profile Data
SIC - Industry Classification
2836 - Biological products, except diagnostic
Incorporation Information
BC, CA, 2018
Employees
6 as of 06/25/2025
Shell
No
Products and Services

The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer.BioVaxys is also developing DPX™+SurMAGE, a, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX™+peanut antigen for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© "neoantigen" tumor cell construct platform targeting ovarian cancer.

Company Facilities

The company has an office in Etobicoke, Ontario, as well as a US office in Miami, FL

Company Notes
Formerly=Lions Bay Mining Corporation until 10-2020
OTCQB Venture Market Logo
Joined OTCQB 07/2024
The Company Profile data was verified by the issuer within the previous 6 months.
This company has certified to OTC Markets Group that it is eligible to rely on the exemption from registration under Securities and Exchange Act Rule 12g3-2(b).
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.